Good evening :)
$
₹
Trinity Biotech plc

Trinity Biotech plc

TRIB

NASDAQ
Asset Logo

Trinity Biotech plc

TRIB

NASDAQ
$5.781.84% (-0.10)
$
₹
$5.781.84% (-0.10)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $5.2M the stock is ranked 5916

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

5.74
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-60
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.30
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-85.36%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on consolidated analysts reports

?

Buy, Sell and Hold recommendations are not available

Price Upside

-49.11%

Earnings Growth

—

Rev. Growth

+35.89%

See Detailed Forecast

Company Profile

Company Profile

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. It has a strategic collaboration agreement with Echelon Data Centres to develop advanced liquid cooling solutions for AI infrastructure. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. It has a strategic collaboration agreement with Echelon Data Centres to develop advanced liquid cooling solutions for AI infrastructure. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
42.94
42.94
1Y Return
7.25%
7.25%
Buy Reco %
82.14
82.14
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
58.29
58.29
1Y Return
12.11%
12.11%
Buy Reco %
76.47
76.47
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.89
38.89
1Y Return
10.7%
10.7%
Buy Reco %
83.33
83.33
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
25.78
25.78
1Y Return
15.97%
15.97%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
36.17
36.17
1Y Return
6.31%
6.31%
Buy Reco %
76.66
76.66
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies -49.11% growth, versus a trailing 3-year CAGR of -24.69%.

2026
Current$5.89Baseline
Analyst Target - 1 year
Target$3-49.11%

All values in $

202220232024202520262027$10.19$17.69$25.18Target-49.11%
2026
Current$5.89Baseline
Analyst Target - 1 year
Target$3-49.11%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 35.89% growth, versus a trailing 3-year CAGR of -11.20%.

2025
Current$43.78Baseline
Forecast for Dec 2026
High$59.5+35.89%
Average$59.5+35.89%
Low$59.5+35.89%

All values in $ Million

20212022202320242025202681.1462.5256.8361.5543.78Low+35.89%Average+35.89%High+35.89%
2025
Current$43.78Baseline
Forecast for Dec 2026
High$59.5+35.89%
Average$59.5+35.89%
Low$59.5+35.89%

All values in $ Million

Financials

Financials

Income

Balance Sheet

Cash Flow

14.2
-5.1
11
-17.4
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Revenue
Net Income
Financial YearQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Total Revenue14.7014.7015.8415.1515.857.57-14.24-11.06
Net Income-3.31-3.31-6.75-4.75-16.95-8.80--5.11--17.46
Net Profit Margin-22.55%-22.55%-42.64%-31.40%-106.93%-116.20%--35.87%--157.83%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Trinity Biotech plc -5.740.30
Abbott Laboratories42.943.701.56
Intuitive Surgical Inc58.299.742.04
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare TRIB with any stock or ETF
Compare TRIB with any stock or ETF
Comparing from
TRIB
ABT
ISRG
Loading...

Frequently asked questions

  1. Trinity Biotech plc (TRIB) share price today is $5.78 as of November 6, 2026 at 10:11 PM IST. The stock touched a day high of $6.15 and a day low of $5.20.

  2. Trinity Biotech plc stock trades on NASDAQ under the ticker symbol TRIB.

  3. Trinity Biotech plc's market capitalization is $5.22M as of November 6, 2026 at 10:11 PM IST.

  4. Trinity Biotech plc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Trinity Biotech plc's price-to-book (P/B) ratio is 5.74 as of November 6, 2026.

  6. Yes, You can buy Trinity Biotech plc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Trinity Biotech plc shares in three steps: 1. Search Trinity Biotech plc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Trinity Biotech plc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Trinity Biotech plc (TRIB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.7283 shares at the current price of $5.78.

Loading...